Investor Relations

Listed On The Shanghai Stock Exchange In June 2001, With A Maximum Market Value Of 47.5 Billion

Ad hoc announcement pursuant to Art. 53 LR-JCARE Supplemental Announcement on the Livzon Group Entering into the Patent and Technology Transfer Agreement

Time:2023-07-21

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Livzon Group Entering into The Patent and Technology Transfer Agreement

Time:2023-07-20

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining the Approval of Drug Clinical Trials for Recombinant SARS-COV-2 Bivalent (Original/Omicron XBB) Fusion Protein Vaccine (CHO Cell)

Time:2023-07-14

Ad hoc announcement pursuant to Art. 53 LR-Announcement on the Implementation of 2022 Profit Distribution of JCARE

Time:2023-07-13

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining the Drug Registration Certificate

Time:2023-07-11

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Cancellation of the Treasury Shares Previously Repurchased

Time:2023-07-03

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on The Initiation of Phase Ⅲ Clinical Trial of Recombinant Anti-Human IL-17A/F Humanized Monoclonal Antibody Injection

Time:2023-06-30

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining the Drug Registration Certificate

Time:2023-06-13

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Resolutions of 2022 Annual General Meeting

Time:2023-06-09

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Company’s Drug Passing the Consistency Evaluation of Generic Drugs

Time:2023-06-07

< 1...121314...16 >